Abstract
During the past 5 years a large number of publications have appeared in the literature on the palliative effect of luteinizing hormone-releasing hormone (LH-RH) analogues given to patients with prostate cancer who would have otherwise been treated by either orchiectomy or estrogens (Borgman et al. 1982; Happ et al. 1986; Labrie et al. 1983; Papadopoulos et al. 1986; Parmar et al. 1985; Roger et al. 1985).
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
References
Borgmann V, Hardt W, Schmid-Gollwitzer M, Adenauer H, Nagel R (1982) Sustained suppression of testosterone production by the luteinising-hormone-releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet I: 1097–1099
Happ J, Schultheiss H, Jacobi GH, Wenderoth UK, Buttenschôn K, Miesel K, Spahn H, Hor G (1986) Pharmacodynamics, pharmacokinetics and bioavailability of the prolonged LH-RH agonist Decapeptyl SR. Eur J Cancer Clin Oncol 22: 742; Abstr. III - 2
Jacobi GH, Wenderoth UK (1982) Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension. Eur Urol 8: 129–134
Labrie F, Dupont A, Bélanger A, Lacoursiere Y, Raynaud JP, Husson JM, Gareau J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4: 579–594
Papadopoulos I, Kleinschmidt K, Weißbach L (1986) Behandlung des fortgeschrittenen Prostatakarzinoms mit der Depotform eines LH-RH-Analogons (Decapeptyl®) Akt Urol 17: 315–319
Parmaf H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV (1985) Randomised controlled study of orchidectomy vs. long-acting D-Trp-6-LH-RH microcapsules in advanced prostatic carcinoma. Lancet II: 1201–1205
Roger M, Duchier J, Lahlou N, Nahoul K, Schally AV (1985) Treatment of prostatic carcinoma with D-Trp-6-LH-RH: Plasma hormone levels after daily subcutaneous injections and periodic administration of delayed-release preparations. Prostate 7: 271–282
Wenderoth UK, Happ J, Krause U, Adenauer H, Jacobi GH (1982) Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients. Eur Urol 8: 343–347
Wenderoth UK, Jacobi GH (1983) Gonadotropin-releasing hormone analogue for palliation of carcinoma of the prostate. A new approach for the classical concept. World J Urol 1: 40–48
Wenderoth UK, Jacobi GH (1985) Langzeitergebnisse mit dem Gn-RH-Analogon Buserelin (Suprefact®) bei der Behandlung des fortgeschrittenen Prostatakarzinoms seit 1981. Akt Urol 16: 58–63
Wenderoth UK, Spindler HW, Jacobi GH (1986) Fünfwöchentliche intramuskuläre Applikation des Gn-RH-Analogs Decapeptyl-Depot bei fortgeschrittenem Prostatakarzinom Akt Urol 17: 320–323
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Jacobi, G.H., Wenderoth, U.K., v. Wallenberg, H., Gatto, M., Hohenfellner, R. (1988). LH-RH Analogues for Palliation of Advanced Prostatic Carcinoma. A Critical Review After Five Years of Experience. In: Höffken, K. (eds) LH-RH Agonists in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73530-1_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-73530-1_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73532-5
Online ISBN: 978-3-642-73530-1
eBook Packages: Springer Book Archive